New development of lipid-lowering therapy of coronary heart disease: Evinacumab / 中国临床药理学与治疗学
Chinese Journal of Clinical Pharmacology and Therapeutics
;
(12): 362-364, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-1014853
ABSTRACT
Homozygous familial hypercholesterolemia is a rare genetic disorder of lipid metabolism, traditional lipid-lowering therapies such as statins and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have little efficacy in these patients. Evinacumab can reduce the levels of LDL-C effectively. In this review, we summarize the latest advances in Evinacumab, and review the phase 2 and phase 3 clinical trials results, adverse events, and the clinical trials results in progress of Evinacumab. Finally, we discuss the current status of Evinacumab in the clinical works.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Clinical Pharmacology and Therapeutics
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS